Three patents currently held, every record listed here
4 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
2 more records may belong here and await a decision; they are not counted.
The next term ends in Mar 2028. from the record
Of the 4 now held by other companies, 2 name GlaxoSmithKline Intellectual Property Limited as their current owner, and 2 more name another party. Each row says which.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
3
Ending by 2030
Mar 2028
Next term end
2
Patent families
When these terms end
Each bar runs from grant to computed term end. 2006 to 2030.
US 9,168,286
Methods and Compositions for Use in Treatment of Patients with Autoantibody Positive Disease
Mar 18, 2029
20112016202120262030
Every computed term in this portfolio is shown above.Updated Nov 14, 2026 · includes USPTO assignment & status data published Nov 14, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Only 2 of the currently held patents qualify as notable.
Notable
Ends May 2030 · High confidence
Also notable
Ends Jan 2029 · High confidence
Albumin Fusion Proteins
US 8,334,365
Cited by 35 later US patents, top 25% of utility patents granted in 2012 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2030.
Antibodies Against Nogo Receptor
US 7,973,139
The most cited patent in this portfolio, cited by 42 later US patents, top 25% of utility patents granted in 2011 in our data. Protection runs to 2029.
Formerly held, still cited
Notable
Ends Apr 2027 · High confidence
The most cited patent in this portfolio, cited by 241 later US patents, top 5% of utility patents granted in 2006 in our data. Protection runs to 2027.
now held by Novozymes Biopharma DK A/S
Also notable
Ends Mar 2029 · High confidence
Cited by 35 later US patents, top 25% of utility patents granted in 2015 in our data, and renewed at every maintenance window due so far. Protection runs to 2029.
now held by GlaxoSmithKline Intellectual Property Limited
Fee deadlines
No maintenance fee falls due on this company's record before Nov 10, 2027.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
What they patent
The 1 largest of its 2 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
| Albumin Fusion Proteins | 2 in force | to May 2030 |
Patents held now
Soonest term end first.
Showing 1 to 3 of 3
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,969,538 | Albumin Fusion Proteins In force · High confidence | In force | High confidence | |
| US 7,973,139 | Antibodies Against Nogo Receptor In force · High confidence | In force | High confidence | |
| US 8,334,365 | Albumin Fusion Proteins In force · High confidence | In force | High confidence |
Also on record, not counted in the 3: 4 patents in force now held by others · 110 patents ended · 234 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
19 terminal disclaimers are on file with no resolved reference. No cap is applied and none is guessed